<?xml version="1.0" encoding="UTF-8"?>
<p>In a cohort of 53 severely ill COVID-19 patients treated with remdesivir and observed for 18 days, 68% of patients improved in oxygen-support status, with a mortality of 13% overall (
 <xref rid="B116" ref-type="bibr">116</xref>). In a preliminary report of a randomized trial of 1,059 patients with COVID-19, those who received remdesivir had a faster recovery than patients who received a placebo (
 <xref rid="B90" ref-type="bibr">90</xref>). Goldman et al. (
 <xref rid="B117" ref-type="bibr">117</xref>) found that in 397 severe COVID-19 pneumonia patients without mechanical ventilation at baseline, there was no significant difference if they were treated for 5 or 10 days. However, in a randomized clinical trial of 158 patients, remdesivir was not associated with a significant clinical improvement compared to the placebo group comprised of 78 patients (
 <xref rid="B91" ref-type="bibr">91</xref>). Numerous clinical trials are ongoing to test remdesivir and its safety against COVID-19 infection.
</p>
